肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的临床效果  

Clinical effect of Feitai Capsules combined with Western antituberculosis drug in the treatment of preliminary smear-positive pulmonary tuberculosis

作　　者：吴先辉[1] 易书林 WU Xian-hui;YI Shu-lin(Yingtan Center for Disease Control and Prevention,Jiangxi Province,Yingtan335000,China;Department of Infectious Diseases,Yingtan People′s Hospital(Railway Branch),Jiangxi Province,Yingtan335000,China)

机构地区：[1]江西省鹰潭市疾病预防控制中心,江西鹰潭335000 [2]江西省鹰潭市人民医院铁路分院感染科,江西鹰潭335000

出　　处：《中国当代医药》2020年第13期137-140,共4页China Modern Medicine

基　　金：江西省鹰潭市科学技术局科技计划项目([2017]2c-50-37)。

摘　　要：目的探讨肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的效果和安全性。方法选取2016年1月~2018年12月在鹰潭市人民医院铁路分院进行治疗的150例初治涂阳肺结核患者作为研究对象,通过计算机生成的随机数,将患者随机分为对照组(n=75)和研究组(n=75)。对照组患者予2HRZE/4HR方案,研究组患者在对照组基础上加用肺泰胶囊治疗。比较两组患者的临床疗效;比较两组患者的痰菌阴转率;比较两组患者的肺部病灶吸收、空洞闭合、临床症状改善情况;比较两组患者的不良反应总发生率。结果研究组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。研究组患者治疗2、5、6个月末的痰菌阴转率均高于对照组,差异有统计学意义(P<0.05)。治疗后,研究组患者的肺部病灶吸收率、空洞闭合率和临床症状改善率均高于对照组,差异有统计学意义(P<0.05)。研究组患者的病灶吸收时间、空洞闭合时间及临床症状改善时间均短于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的效果确切,安全性好,肺泰胶囊可作为初治涂阳肺结核的辅助治疗方法。Objective To investigate the effect and safety of Feitai Capsules combined with Western antituberculosis drug in the treatment of preliminary smear-positive pulmonary tuberculosis.Methods From January 2016 to December 2018,150 patients with newly diagnosed smear-positive pulmonary tuberculosis who were treated in the Yingtan People′s Hospital(Railway Branch)were selected as the research subjects.The patients were randomly divided into the control group(n=75)and study group(n=75)using computer-generated random number.In the control group,2HRZE/4HR regimen was used,while in the study group,Feitai Capsules on the basis of the control group were added.The clinical efficacy of the two groups was compared.The sputum negative conversion rate of the two groups was compared.The lung lesion absorption,cavity closure and clinical symptom improvement were compared between the two groups.The total incidence of adverse reactions was compared between the two groups.Results The total effective rate in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).The sputum negative conversion rate in the study group was higher than that in the control group at the end of 2,5,and 6 months treatment,the differences were statistically significant(P<0.05).After treatment,the lung lesion absorption rate,cavity closure rate,and clinical symptom improvement rate in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The lesion absorption time,cavity closure time and clinical symptom improvement time of patients in the study group were all shorter than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Feitai Capsules combined with Western antituberculosis drug for the treatment of smear-positive pulmonary tuberculosis are effective and safe.Feitai Capsules

关 键 词：肺泰胶囊 肺结核 痰菌阴转 不良反应 

分 类 号：R521[医药卫生—内科学]